Original Article

Does the Number of Positive Nodes in pN1 Premenopausal HR+/HER2− Breast Cancer Patients with a Low 21-Gene Recurrence Score Predict Chemotherapy Benefit?

Objectives: The RxPONDER trial showed premenopausal patients with pT1-2 N1 hormone receptor-positive (HR+)/HER2− breast cancer benefit from chemotherapy regardless of 21-gene recurrence score (RS), but it did not analyze whether the number of positive lymph nodes (+LNs) was correlative of outcomes. Our study sought to evaluate whether the number of…